1	Earnings	_	NNS	_	_	11	SBJ	_	_
2	for	_	IN	_	_	1	NMOD	_	_
3	most	_	JJS	_	_	2	PMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	nation	_	NN	_	_	10	NMOD	_	_
7	's	_	POS	_	_	6	SUFFIX	_	_
8	major	_	JJ	_	_	10	NMOD	_	_
9	pharmaceutical	_	JJ	_	_	10	NMOD	_	_
10	makers	_	NNS	_	_	4	PMOD	_	_
11	are	_	VBP	_	_	0	ROOT	_	_
12	believed	_	VBN	_	_	11	VC	_	_
13	to	_	TO	_	_	12	OPRD	_	_
14	have	_	VB	_	_	13	IM	_	_
15	moved	_	VBN	_	_	14	VC	_	_
16	ahead	_	RB	_	_	15	DIR	_	_
17	briskly	_	RB	_	_	15	MNR	_	_
18	in	_	IN	_	_	15	TMP	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	third	_	JJ	_	_	21	NMOD	_	_
21	quarter	_	NN	_	_	18	PMOD	_	_
22	,	_	,	_	_	15	P	_	_
23	as	_	IN	_	_	15	ADV	_	_
24	companies	_	NNS	_	_	31	SBJ	_	_
25	with	_	IN	_	_	24	NMOD	_	_
26	newer	_	JJR	_	_	30	NMOD	_	_
27	,	_	,	_	_	30	P	_	_
28	big-selling	_	JJ	_	_	30	NMOD	_	_
29	prescription	_	NN	_	_	30	NMOD	_	_
30	drugs	_	NNS	_	_	25	PMOD	_	_
31	fared	_	VBD	_	_	23	SUB	_	_
32	especially	_	RB	_	_	31	MNR	_	_
33	well	_	RB	_	_	32	AMOD	_	_
34	.	_	.	_	_	11	P	_	_

1	For	_	IN	_	_	15	ADV	_	_
2	the	_	DT	_	_	5	NMOD	_	_
3	third	_	JJ	_	_	5	NMOD	_	_
4	consecutive	_	JJ	_	_	5	NMOD	_	_
5	quarter	_	NN	_	_	1	PMOD	_	_
6	,	_	,	_	_	15	P	_	_
7	however	_	RB	_	_	15	ADV	_	_
8	,	_	,	_	_	15	P	_	_
9	most	_	JJS	_	_	15	SBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	companies	_	NNS	_	_	14	NMOD	_	_
13	'	_	POS	_	_	12	SUFFIX	_	_
14	revenues	_	NNS	_	_	10	PMOD	_	_
15	were	_	VBD	_	_	0	ROOT	_	_
16	battered	_	VBN	_	_	15	VC	_	_
17	by	_	IN	_	_	16	LGS	_	_
18	adverse	_	JJ	_	_	20	NMOD	_	_
19	foreign-currency	_	NN	_	_	20	NMOD	_	_
20	translations	_	NNS	_	_	17	PMOD	_	_
21	as	_	IN	_	_	16	PRP	_	_
22	a	_	DT	_	_	23	NMOD	_	_
23	result	_	NN	_	_	21	PMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	the	_	DT	_	_	27	NMOD	_	_
26	strong	_	JJ	_	_	27	NMOD	_	_
27	dollar	_	NN	_	_	24	PMOD	_	_
28	abroad	_	RB	_	_	27	LOC	_	_
29	.	_	.	_	_	15	P	_	_

1	Analysts	_	NNS	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	Merck	_	NNP	_	_	25	SBJ	_	_
5	&	_	CC	_	_	4	COORD	_	_
6	Co.	_	NNP	_	_	5	CONJ	_	_
7	,	_	,	_	_	6	P	_	_
8	Eli	_	NNP	_	_	9	NAME	_	_
9	Lilly	_	NNP	_	_	6	COORD	_	_
10	&	_	CC	_	_	9	COORD	_	_
11	Co.	_	NNP	_	_	13	COORD	_	_
12	,	_	,	_	_	10	P	_	_
13	Warner-Lambert	_	NNP	_	_	10	CONJ	_	_
14	Co.	_	NNP	_	_	13	POSTHON	_	_
15	and	_	CC	_	_	13	COORD	_	_
16	the	_	DT	_	_	19	NMOD	_	_
17	Squibb	_	NNP	_	_	19	NMOD	_	_
18	Corp.	_	NNP	_	_	19	NMOD	_	_
19	unit	_	NN	_	_	15	CONJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	Bristol-Myers	_	NNP	_	_	22	NAME	_	_
22	Squibb	_	NNP	_	_	20	PMOD	_	_
23	Co.	_	NNP	_	_	22	POSTHON	_	_
24	all	_	DT	_	_	25	DEP	_	_
25	benefited	_	VBD	_	_	3	SUB	_	_
26	from	_	IN	_	_	25	ADV	_	_
27	strong	_	JJ	_	_	28	NMOD	_	_
28	sales	_	NNS	_	_	26	PMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	relatively	_	RB	_	_	31	AMOD	_	_
31	new	_	JJ	_	_	34	NMOD	_	_
32	,	_	,	_	_	34	P	_	_
33	higher-priced	_	JJ	_	_	34	NMOD	_	_
34	medicines	_	NNS	_	_	29	PMOD	_	_
35	that	_	WDT	_	_	36	SBJ	_	_
36	provide	_	VBP	_	_	34	NMOD	_	_
37	wide	_	JJ	_	_	39	NMOD	_	_
38	profit	_	NN	_	_	39	NMOD	_	_
39	margins	_	NNS	_	_	36	OBJ	_	_
40	.	_	.	_	_	2	P	_	_

1	Less	_	RBR	_	_	2	AMOD	_	_
2	robust	_	JJ	_	_	3	NMOD	_	_
3	earnings	_	NNS	_	_	10	SBJ	_	_
4	at	_	IN	_	_	3	LOC	_	_
5	Pfizer	_	NNP	_	_	4	PMOD	_	_
6	Inc.	_	NNP	_	_	5	POSTHON	_	_
7	and	_	CC	_	_	5	COORD	_	_
8	Upjohn	_	NNP	_	_	7	CONJ	_	_
9	Co.	_	NNP	_	_	8	POSTHON	_	_
10	were	_	VBD	_	_	0	ROOT	_	_
11	attributed	_	VBN	_	_	10	VC	_	_
12	to	_	TO	_	_	11	ADV	_	_
13	those	_	DT	_	_	14	NMOD	_	_
14	companies	_	NNS	_	_	17	NMOD	_	_
15	'	_	POS	_	_	14	SUFFIX	_	_
16	older	_	JJR	_	_	17	NMOD	_	_
17	products	_	NNS	_	_	12	PMOD	_	_
18	,	_	,	_	_	17	P	_	_
19	many	_	JJ	_	_	22	SBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	which	_	WDT	_	_	20	PMOD	_	_
22	face	_	VBP	_	_	17	NMOD	_	_
23	stiffening	_	JJ	_	_	24	NMOD	_	_
24	competition	_	NN	_	_	22	OBJ	_	_
25	from	_	IN	_	_	24	NMOD	_	_
26	generic	_	JJ	_	_	27	NMOD	_	_
27	drugs	_	NNS	_	_	25	PMOD	_	_
28	and	_	CC	_	_	27	COORD	_	_
29	other	_	JJ	_	_	30	NMOD	_	_
30	medicines	_	NNS	_	_	28	CONJ	_	_
31	.	_	.	_	_	10	P	_	_

1	Joseph	_	NNP	_	_	2	NAME	_	_
2	Riccardo	_	NNP	_	_	13	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	an	_	DT	_	_	5	NMOD	_	_
5	analyst	_	NN	_	_	2	APPO	_	_
6	with	_	IN	_	_	5	NMOD	_	_
7	Bear	_	NNP	_	_	6	PMOD	_	_
8	,	_	,	_	_	7	P	_	_
9	Stearns	_	NNP	_	_	7	COORD	_	_
10	&	_	CC	_	_	9	COORD	_	_
11	Co.	_	NNP	_	_	10	CONJ	_	_
12	,	_	,	_	_	2	P	_	_
13	said	_	VBD	_	_	0	ROOT	_	_
14	that	_	IN	_	_	13	OBJ	_	_
15	over	_	IN	_	_	23	TMP	_	_
16	the	_	DT	_	_	19	NMOD	_	_
17	past	_	JJ	_	_	19	NMOD	_	_
18	few	_	JJ	_	_	19	NMOD	_	_
19	years	_	NNS	_	_	15	PMOD	_	_
20	most	_	JJS	_	_	22	NMOD	_	_
21	drug	_	NN	_	_	22	NMOD	_	_
22	makers	_	NNS	_	_	23	SBJ	_	_
23	have	_	VBP	_	_	14	SUB	_	_
24	shed	_	VBN	_	_	23	VC	_	_
25	their	_	PRP$	_	_	27	NMOD	_	_
26	slow-growing	_	JJ	_	_	27	NMOD	_	_
27	businesses	_	NNS	_	_	24	OBJ	_	_
28	and	_	CC	_	_	24	COORD	_	_
29	instituted	_	VBN	_	_	28	CONJ	_	_
30	other	_	JJ	_	_	32	NMOD	_	_
31	cost	_	NN	_	_	32	NMOD	_	_
32	savings	_	NNS	_	_	29	OBJ	_	_
33	,	_	,	_	_	32	P	_	_
34	such	_	JJ	_	_	35	DEP	_	_
35	as	_	IN	_	_	32	NMOD	_	_
36	consolidating	_	VBG	_	_	35	PMOD	_	_
37	manufacturing	_	NN	_	_	38	NMOD	_	_
38	plants	_	NNS	_	_	36	OBJ	_	_
39	and	_	CC	_	_	38	COORD	_	_
40	administrative	_	JJ	_	_	41	NMOD	_	_
41	staffs	_	NNS	_	_	39	CONJ	_	_
42	.	_	.	_	_	13	P	_	_

1	As	_	IN	_	_	9	PRP	_	_
2	a	_	DT	_	_	3	NMOD	_	_
3	result	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	9	P	_	_
5	``	_	``	_	_	9	P	_	_
6	major	_	JJ	_	_	8	NMOD	_	_
7	new	_	JJ	_	_	8	NMOD	_	_
8	products	_	NNS	_	_	9	SBJ	_	_
9	are	_	VBP	_	_	26	OBJ	_	_
10	having	_	VBG	_	_	9	VC	_	_
11	significant	_	JJ	_	_	12	NMOD	_	_
12	impact	_	NN	_	_	10	OBJ	_	_
13	,	_	,	_	_	10	P	_	_
14	even	_	RB	_	_	15	PMOD	_	_
15	on	_	IN	_	_	10	ADV	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	company	_	NN	_	_	15	PMOD	_	_
18	with	_	IN	_	_	17	NMOD	_	_
19	very	_	RB	_	_	20	AMOD	_	_
20	large	_	JJ	_	_	21	NMOD	_	_
21	revenues	_	NNS	_	_	18	PMOD	_	_
22	,	_	,	_	_	26	P	_	_
23	''	_	''	_	_	26	P	_	_
24	Mr.	_	NNP	_	_	25	TITLE	_	_
25	Riccardo	_	NNP	_	_	26	SBJ	_	_
26	said	_	VBD	_	_	0	ROOT	_	_
27	.	_	.	_	_	26	P	_	_

1	Analysts	_	NNS	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	profit	_	NN	_	_	17	SBJ	_	_
4	for	_	IN	_	_	3	NMOD	_	_
5	the	_	DT	_	_	11	NMOD	_	_
6	dozen	_	NN	_	_	11	NMOD	_	_
7	or	_	CC	_	_	6	COORD	_	_
8	so	_	RB	_	_	7	CONJ	_	_
9	big	_	JJ	_	_	11	NMOD	_	_
10	drug	_	NN	_	_	11	NMOD	_	_
11	makers	_	NNS	_	_	4	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	as	_	IN	_	_	11	NMOD	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	group	_	NN	_	_	13	PMOD	_	_
16	,	_	,	_	_	11	P	_	_
17	is	_	VBZ	_	_	2	OBJ	_	_
18	estimated	_	VBN	_	_	17	VC	_	_
19	to	_	TO	_	_	18	OPRD	_	_
20	have	_	VB	_	_	19	IM	_	_
21	climbed	_	VBN	_	_	20	VC	_	_
22	between	_	IN	_	_	24	DEP	_	_
23	11	_	CD	_	_	24	COORD	_	_
24	%	_	NN	_	_	21	EXT	_	_
25	and	_	CC	_	_	24	COORD	_	_
26	14	_	CD	_	_	25	CONJ	_	_
27	%	_	NN	_	_	26	COORD	_	_
28	.	_	.	_	_	2	P	_	_

1	While	_	IN	_	_	16	ADV	_	_
2	that	_	DT	_	_	3	SBJ	_	_
3	's	_	VBZ	_	_	1	SUB	_	_
4	not	_	RB	_	_	3	ADV	_	_
5	spectacular	_	JJ	_	_	3	PRD	_	_
6	,	_	,	_	_	16	P	_	_
7	Neil	_	NNP	_	_	8	NAME	_	_
8	Sweig	_	NNP	_	_	16	SBJ	_	_
9	,	_	,	_	_	8	P	_	_
10	an	_	DT	_	_	11	NMOD	_	_
11	analyst	_	NN	_	_	8	APPO	_	_
12	with	_	IN	_	_	11	NMOD	_	_
13	Prudential	_	NNP	_	_	14	NAME	_	_
14	Bache	_	NNP	_	_	12	PMOD	_	_
15	,	_	,	_	_	8	P	_	_
16	said	_	VBD	_	_	0	ROOT	_	_
17	that	_	IN	_	_	16	OBJ	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	rate	_	NN	_	_	22	SBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	growth	_	NN	_	_	20	PMOD	_	_
22	will	_	MD	_	_	17	SUB	_	_
23	``	_	``	_	_	22	P	_	_
24	look	_	VB	_	_	22	VC	_	_
25	especially	_	RB	_	_	26	AMOD	_	_
26	good	_	JJ	_	_	24	PRD	_	_
27	as	_	IN	_	_	26	AMOD	_	_
28	compared	_	VBN	_	_	27	SUB	_	_
29	to	_	TO	_	_	28	ADV	_	_
30	other	_	JJ	_	_	31	NMOD	_	_
31	companies	_	NNS	_	_	29	PMOD	_	_
32	if	_	IN	_	_	24	ADV	_	_
33	the	_	DT	_	_	34	NMOD	_	_
34	economy	_	NN	_	_	35	SBJ	_	_
35	turns	_	VBZ	_	_	32	SUB	_	_
36	downward	_	RB	_	_	35	DIR	_	_
37	.	_	.	_	_	16	P	_	_
38	''	_	''	_	_	16	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Sweig	_	NNP	_	_	3	SBJ	_	_
3	estimated	_	VBD	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	Merck	_	NNP	_	_	7	NMOD	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	profit	_	NN	_	_	11	SBJ	_	_
8	for	_	IN	_	_	7	NMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	quarter	_	NN	_	_	8	PMOD	_	_
11	rose	_	VBD	_	_	4	SUB	_	_
12	by	_	IN	_	_	11	EXT	_	_
13	about	_	RB	_	_	15	NMOD	_	_
14	22	_	CD	_	_	13	DEP	_	_
15	%	_	NN	_	_	12	PMOD	_	_
16	,	_	,	_	_	11	P	_	_
17	propelled	_	VBN	_	_	11	ADV	_	_
18	by	_	IN	_	_	17	LGS	_	_
19	sales	_	NNS	_	_	18	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	its	_	PRP$	_	_	22	NMOD	_	_
22	line-up	_	NN	_	_	20	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	fast-growing	_	JJ	_	_	26	NMOD	_	_
25	prescription	_	NN	_	_	26	NMOD	_	_
26	drugs	_	NNS	_	_	23	PMOD	_	_
27	,	_	,	_	_	26	P	_	_
28	including	_	VBG	_	_	26	NMOD	_	_
29	its	_	PRP$	_	_	31	NMOD	_	_
30	anti-cholesterol	_	JJ	_	_	31	NMOD	_	_
31	drug	_	NN	_	_	28	PMOD	_	_
32	,	_	,	_	_	31	P	_	_
33	Mevacor	_	NNP	_	_	31	APPO	_	_
34	;	_	:	_	_	31	P	_	_
35	a	_	DT	_	_	39	NMOD	_	_
36	high	_	JJ	_	_	39	NMOD	_	_
37	blood	_	NN	_	_	39	NMOD	_	_
38	pressure	_	NN	_	_	39	NMOD	_	_
39	medicine	_	NN	_	_	31	COORD	_	_
40	,	_	,	_	_	39	P	_	_
41	Vasotec	_	NNP	_	_	39	APPO	_	_
42	;	_	:	_	_	39	P	_	_
43	Primaxin	_	NNP	_	_	39	COORD	_	_
44	,	_	,	_	_	43	P	_	_
45	an	_	DT	_	_	46	NMOD	_	_
46	antibiotic	_	NN	_	_	43	APPO	_	_
47	,	_	,	_	_	43	P	_	_
48	and	_	CC	_	_	43	COORD	_	_
49	Pepcid	_	NNP	_	_	48	CONJ	_	_
50	,	_	,	_	_	49	P	_	_
51	an	_	DT	_	_	53	NMOD	_	_
52	anti-ulcer	_	JJ	_	_	53	NMOD	_	_
53	medication	_	NN	_	_	49	APPO	_	_
54	.	_	.	_	_	3	P	_	_

1	Profit	_	NN	_	_	2	SBJ	_	_
2	climbed	_	VBD	_	_	28	OBJ	_	_
3	even	_	RB	_	_	4	DEP	_	_
4	though	_	IN	_	_	2	ADV	_	_
5	Merck	_	NNP	_	_	7	NMOD	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	sales	_	NNS	_	_	8	SBJ	_	_
8	were	_	VBD	_	_	4	SUB	_	_
9	reduced	_	VBN	_	_	8	VC	_	_
10	by	_	IN	_	_	9	EXT	_	_
11	``	_	``	_	_	10	P	_	_
12	one	_	CD	_	_	14	DEP	_	_
13	to	_	TO	_	_	14	DEP	_	_
14	three	_	CD	_	_	16	NMOD	_	_
15	percentage	_	NN	_	_	16	NMOD	_	_
16	points	_	NNS	_	_	10	PMOD	_	_
17	''	_	''	_	_	10	P	_	_
18	as	_	IN	_	_	9	PRP	_	_
19	a	_	DT	_	_	20	NMOD	_	_
20	result	_	NN	_	_	18	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	the	_	DT	_	_	24	NMOD	_	_
23	strong	_	JJ	_	_	24	NMOD	_	_
24	dollar	_	NN	_	_	21	PMOD	_	_
25	,	_	,	_	_	28	P	_	_
26	Mr.	_	NNP	_	_	27	TITLE	_	_
27	Sweig	_	NNP	_	_	28	SBJ	_	_
28	said	_	VBD	_	_	0	ROOT	_	_
29	.	_	.	_	_	28	P	_	_

1	In	_	IN	_	_	9	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	third	_	JJ	_	_	4	NMOD	_	_
4	quarter	_	NN	_	_	1	PMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	1988	_	CD	_	_	5	PMOD	_	_
7	,	_	,	_	_	9	P	_	_
8	Merck	_	NNP	_	_	9	SBJ	_	_
9	earned	_	VBD	_	_	0	ROOT	_	_
10	$	_	$	_	_	9	OBJ	_	_
11	311.8	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	,	_	,	_	_	10	P	_	_
14	or	_	CC	_	_	10	COORD	_	_
15	79	_	CD	_	_	16	NMOD	_	_
16	cents	_	NNS	_	_	14	CONJ	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	16	ADV	_	_
19	.	_	.	_	_	9	P	_	_

1	In	_	IN	_	_	9	LOC	_	_
2	Rahway	_	NNP	_	_	1	PMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	N.J.	_	NNP	_	_	2	APPO	_	_
5	,	_	,	_	_	2	P	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	Merck	_	NNP	_	_	8	NMOD	_	_
8	spokesman	_	NN	_	_	9	SBJ	_	_
9	said	_	VBD	_	_	0	ROOT	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	company	_	NN	_	_	12	SBJ	_	_
12	does	_	VBZ	_	_	9	OBJ	_	_
13	n't	_	RB	_	_	12	ADV	_	_
14	make	_	VB	_	_	12	VC	_	_
15	earnings	_	NN	_	_	16	NMOD	_	_
16	projections	_	NNS	_	_	14	OBJ	_	_
17	.	_	.	_	_	9	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Sweig	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	he	_	PRP	_	_	5	SBJ	_	_
5	estimated	_	VBD	_	_	3	OBJ	_	_
6	that	_	IN	_	_	5	OBJ	_	_
7	Lilly	_	NNP	_	_	9	NMOD	_	_
8	's	_	POS	_	_	7	SUFFIX	_	_
9	earnings	_	NNS	_	_	13	SBJ	_	_
10	for	_	IN	_	_	9	NMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	quarter	_	NN	_	_	10	PMOD	_	_
13	jumped	_	VBD	_	_	6	SUB	_	_
14	about	_	RB	_	_	16	NMOD	_	_
15	20	_	CD	_	_	16	NMOD	_	_
16	%	_	NN	_	_	13	EXT	_	_
17	,	_	,	_	_	13	P	_	_
18	largely	_	RB	_	_	19	PMOD	_	_
19	because	_	IN	_	_	13	PRP	_	_
20	of	_	IN	_	_	19	DEP	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	performance	_	NN	_	_	19	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	its	_	PRP$	_	_	27	NMOD	_	_
25	new	_	JJ	_	_	27	NMOD	_	_
26	anti-depressant	_	NN	_	_	27	NMOD	_	_
27	Prozac	_	NNP	_	_	23	PMOD	_	_
28	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	drug	_	NN	_	_	8	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	introduced	_	VBD	_	_	2	APPO	_	_
5	last	_	JJ	_	_	6	NMOD	_	_
6	year	_	NN	_	_	4	TMP	_	_
7	,	_	,	_	_	2	P	_	_
8	is	_	VBZ	_	_	0	ROOT	_	_
9	expected	_	VBN	_	_	8	VC	_	_
10	to	_	TO	_	_	9	OPRD	_	_
11	generate	_	VB	_	_	10	IM	_	_
12	sales	_	NNS	_	_	11	OBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	about	_	RB	_	_	15	DEP	_	_
15	$	_	$	_	_	13	PMOD	_	_
16	300	_	CD	_	_	15	DEP	_	_
17	million	_	CD	_	_	15	DEP	_	_
18	this	_	DT	_	_	19	NMOD	_	_
19	year	_	NN	_	_	11	TMP	_	_
20	.	_	.	_	_	8	P	_	_

1	``	_	``	_	_	15	P	_	_
2	It	_	PRP	_	_	3	SBJ	_	_
3	's	_	VBZ	_	_	15	OBJ	_	_
4	turning	_	VBG	_	_	3	VC	_	_
5	out	_	RP	_	_	4	PRT	_	_
6	to	_	TO	_	_	4	OPRD	_	_
7	be	_	VB	_	_	6	IM	_	_
8	a	_	DT	_	_	10	NMOD	_	_
9	real	_	JJ	_	_	10	NMOD	_	_
10	blockbuster	_	NN	_	_	7	PRD	_	_
11	,	_	,	_	_	15	P	_	_
12	''	_	''	_	_	15	P	_	_
13	Mr.	_	NNP	_	_	14	TITLE	_	_
14	Sweig	_	NNP	_	_	15	SBJ	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	.	_	.	_	_	15	P	_	_

1	In	_	IN	_	_	9	TMP	_	_
2	last	_	JJ	_	_	3	NMOD	_	_
3	year	_	NN	_	_	6	NMOD	_	_
4	's	_	POS	_	_	3	SUFFIX	_	_
5	third	_	JJ	_	_	6	NMOD	_	_
6	quarter	_	NN	_	_	1	PMOD	_	_
7	,	_	,	_	_	9	P	_	_
8	Lilly	_	NNP	_	_	9	SBJ	_	_
9	earned	_	VBD	_	_	0	ROOT	_	_
10	$	_	$	_	_	9	OBJ	_	_
11	171.4	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	,	_	,	_	_	10	P	_	_
14	or	_	CC	_	_	10	COORD	_	_
15	$	_	$	_	_	14	CONJ	_	_
16	1.20	_	CD	_	_	15	NMOD	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	15	ADV	_	_
19	.	_	.	_	_	9	P	_	_

1	In	_	IN	_	_	5	LOC	_	_
2	Indianapolis	_	NNP	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	Lilly	_	NNP	_	_	5	SBJ	_	_
5	declined	_	VBD	_	_	0	ROOT	_	_
6	comment	_	NN	_	_	5	OBJ	_	_
7	.	_	.	_	_	5	P	_	_

1	Several	_	JJ	_	_	2	NMOD	_	_
2	analysts	_	NNS	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	they	_	PRP	_	_	5	SBJ	_	_
5	expected	_	VBD	_	_	3	OBJ	_	_
6	Warner-Lambert	_	NNP	_	_	8	NMOD	_	_
7	's	_	POS	_	_	6	SUFFIX	_	_
8	profit	_	NN	_	_	5	OBJ	_	_
9	also	_	RB	_	_	10	ADV	_	_
10	to	_	TO	_	_	5	OPRD	_	_
11	increase	_	VB	_	_	10	IM	_	_
12	by	_	IN	_	_	11	EXT	_	_
13	more	_	JJR	_	_	15	DEP	_	_
14	than	_	IN	_	_	15	DEP	_	_
15	20	_	CD	_	_	16	NMOD	_	_
16	%	_	NN	_	_	12	PMOD	_	_
17	from	_	IN	_	_	11	DIR	_	_
18	$	_	$	_	_	17	PMOD	_	_
19	87.7	_	CD	_	_	18	DEP	_	_
20	million	_	CD	_	_	18	DEP	_	_
21	,	_	,	_	_	18	P	_	_
22	or	_	CC	_	_	18	COORD	_	_
23	$	_	$	_	_	22	CONJ	_	_
24	1.25	_	CD	_	_	23	NMOD	_	_
25	a	_	DT	_	_	26	NMOD	_	_
26	share	_	NN	_	_	23	ADV	_	_
27	,	_	,	_	_	18	P	_	_
28	it	_	PRP	_	_	29	SBJ	_	_
29	reported	_	VBD	_	_	18	NMOD	_	_
30	in	_	IN	_	_	29	TMP	_	_
31	the	_	DT	_	_	33	NMOD	_	_
32	like	_	JJ	_	_	33	NMOD	_	_
33	period	_	NN	_	_	30	PMOD	_	_
34	last	_	JJ	_	_	35	NMOD	_	_
35	year	_	NN	_	_	33	TMP	_	_
36	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	praised	_	VBN	_	_	3	VC	_	_
5	by	_	IN	_	_	4	LGS	_	_
6	analysts	_	NNS	_	_	5	PMOD	_	_
7	for	_	IN	_	_	4	PRP	_	_
8	sharply	_	RB	_	_	9	MNR	_	_
9	lowering	_	VBG	_	_	7	PMOD	_	_
10	its	_	PRP$	_	_	11	NMOD	_	_
11	costs	_	NNS	_	_	9	OBJ	_	_
12	in	_	IN	_	_	9	TMP	_	_
13	recent	_	JJ	_	_	14	NMOD	_	_
14	years	_	NNS	_	_	12	PMOD	_	_
15	and	_	CC	_	_	9	COORD	_	_
16	shedding	_	VBG	_	_	15	CONJ	_	_
17	numerous	_	JJ	_	_	18	NMOD	_	_
18	companies	_	NNS	_	_	16	OBJ	_	_
19	with	_	IN	_	_	18	NMOD	_	_
20	low	_	JJ	_	_	22	NMOD	_	_
21	profit	_	NN	_	_	22	NMOD	_	_
22	margins	_	NNS	_	_	19	PMOD	_	_
23	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	5	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	lean	_	JJ	_	_	5	NMOD	_	_
5	operation	_	NN	_	_	10	SBJ	_	_
6	,	_	,	_	_	8	P	_	_
7	analysts	_	NNS	_	_	8	SBJ	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	,	_	,	_	_	8	P	_	_
10	allowed	_	VBD	_	_	8	OBJ	_	_
11	sharp-rising	_	JJ	_	_	12	NMOD	_	_
12	sales	_	NNS	_	_	10	OBJ	_	_
13	from	_	IN	_	_	12	NMOD	_	_
14	its	_	PRP$	_	_	16	NMOD	_	_
15	cholesterol	_	NN	_	_	16	NMOD	_	_
16	drug	_	NN	_	_	13	PMOD	_	_
17	,	_	,	_	_	16	P	_	_
18	Lopid	_	NNP	_	_	16	APPO	_	_
19	,	_	,	_	_	16	P	_	_
20	to	_	TO	_	_	10	OPRD	_	_
21	power	_	VB	_	_	20	IM	_	_
22	earnings	_	NNS	_	_	23	NMOD	_	_
23	growth	_	NN	_	_	21	OBJ	_	_
24	.	_	.	_	_	10	P	_	_

1	Lopid	_	NNP	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	0	ROOT	_	_
4	expected	_	VBN	_	_	3	VC	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	be	_	VB	_	_	5	IM	_	_
7	about	_	RB	_	_	8	DEP	_	_
8	$	_	$	_	_	6	PRD	_	_
9	300	_	CD	_	_	8	DEP	_	_
10	million	_	CD	_	_	8	DEP	_	_
11	this	_	DT	_	_	12	NMOD	_	_
12	year	_	NN	_	_	6	TMP	_	_
13	,	_	,	_	_	6	P	_	_
14	up	_	RB	_	_	6	ADV	_	_
15	from	_	IN	_	_	14	AMOD	_	_
16	$	_	$	_	_	15	PMOD	_	_
17	190	_	CD	_	_	16	DEP	_	_
18	million	_	CD	_	_	16	DEP	_	_
19	in	_	IN	_	_	15	TMP	_	_
20	1988	_	CD	_	_	19	PMOD	_	_
21	.	_	.	_	_	3	P	_	_

1	In	_	IN	_	_	12	LOC	_	_
2	Morris	_	NNP	_	_	3	NAME	_	_
3	Plains	_	NNP	_	_	1	PMOD	_	_
4	,	_	,	_	_	3	P	_	_
5	N.J.	_	NNP	_	_	3	APPO	_	_
6	,	_	,	_	_	3	P	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	spokesman	_	NN	_	_	12	SBJ	_	_
9	for	_	IN	_	_	8	NMOD	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	company	_	NN	_	_	9	PMOD	_	_
12	said	_	VBD	_	_	0	ROOT	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	analysts	_	NNS	_	_	16	NMOD	_	_
15	'	_	POS	_	_	14	SUFFIX	_	_
16	projections	_	NNS	_	_	17	SBJ	_	_
17	are	_	VBP	_	_	12	OBJ	_	_
18	``	_	``	_	_	17	P	_	_
19	in	_	IN	_	_	17	LOC-PRD	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	ballpark	_	NN	_	_	19	PMOD	_	_
22	.	_	.	_	_	12	P	_	_
23	''	_	''	_	_	12	P	_	_

1	Squibb	_	NNP	_	_	3	NMOD	_	_
2	's	_	POS	_	_	1	SUFFIX	_	_
3	profit	_	NN	_	_	34	SBJ	_	_
4	,	_	,	_	_	34	P	_	_
5	estimated	_	VBN	_	_	34	ADV	_	_
6	by	_	IN	_	_	5	LGS	_	_
7	analysts	_	NNS	_	_	6	PMOD	_	_
8	to	_	TO	_	_	5	OPRD	_	_
9	be	_	VB	_	_	8	IM	_	_
10	about	_	RB	_	_	12	NMOD	_	_
11	18	_	CD	_	_	10	DEP	_	_
12	%	_	NN	_	_	13	PMOD	_	_
13	above	_	IN	_	_	9	LOC-PRD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	$	_	$	_	_	13	PMOD	_	_
16	123	_	CD	_	_	15	DEP	_	_
17	million	_	CD	_	_	15	DEP	_	_
18	,	_	,	_	_	15	P	_	_
19	or	_	CC	_	_	15	COORD	_	_
20	$	_	$	_	_	19	CONJ	_	_
21	1.25	_	CD	_	_	20	NMOD	_	_
22	a	_	DT	_	_	23	NMOD	_	_
23	share	_	NN	_	_	20	ADV	_	_
24	,	_	,	_	_	15	P	_	_
25	it	_	PRP	_	_	26	SBJ	_	_
26	earned	_	VBD	_	_	15	NMOD	_	_
27	in	_	IN	_	_	26	TMP	_	_
28	the	_	DT	_	_	30	NMOD	_	_
29	third	_	JJ	_	_	30	NMOD	_	_
30	quarter	_	NN	_	_	27	PMOD	_	_
31	of	_	IN	_	_	30	NMOD	_	_
32	1988	_	CD	_	_	31	PMOD	_	_
33	,	_	,	_	_	15	P	_	_
34	was	_	VBD	_	_	0	ROOT	_	_
35	the	_	DT	_	_	36	NMOD	_	_
36	result	_	NN	_	_	34	PRD	_	_
37	of	_	IN	_	_	36	NMOD	_	_
38	especially	_	RB	_	_	39	AMOD	_	_
39	strong	_	JJ	_	_	40	NMOD	_	_
40	sales	_	NNS	_	_	37	PMOD	_	_
41	of	_	IN	_	_	40	NMOD	_	_
42	its	_	PRP$	_	_	44	NMOD	_	_
43	Capoten	_	NNP	_	_	44	NMOD	_	_
44	drug	_	NN	_	_	41	PMOD	_	_
45	for	_	IN	_	_	44	NMOD	_	_
46	treating	_	VBG	_	_	45	PMOD	_	_
47	high	_	JJ	_	_	49	NMOD	_	_
48	blood	_	NN	_	_	49	NMOD	_	_
49	pressure	_	NN	_	_	46	OBJ	_	_
50	and	_	CC	_	_	49	COORD	_	_
51	other	_	JJ	_	_	53	NMOD	_	_
52	heart	_	NN	_	_	53	NMOD	_	_
53	disease	_	NN	_	_	50	CONJ	_	_
54	.	_	.	_	_	34	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	officially	_	RB	_	_	5	MNR	_	_
5	merged	_	VBN	_	_	3	VC	_	_
6	with	_	IN	_	_	5	ADV	_	_
7	Bristol-Myers	_	NNP	_	_	6	PMOD	_	_
8	Co.	_	NNP	_	_	7	POSTHON	_	_
9	earlier	_	RBR	_	_	11	NMOD	_	_
10	this	_	DT	_	_	11	NMOD	_	_
11	month	_	NN	_	_	5	TMP	_	_
12	.	_	.	_	_	3	P	_	_

1	Bristol-Myers	_	NNP	_	_	2	SBJ	_	_
2	declined	_	VBD	_	_	0	ROOT	_	_
3	to	_	TO	_	_	2	OPRD	_	_
4	comment	_	VB	_	_	3	IM	_	_
5	.	_	.	_	_	2	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Riccardo	_	NNP	_	_	6	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	Bear	_	NNP	_	_	5	NAME	_	_
5	Stearns	_	NNP	_	_	3	PMOD	_	_
6	said	_	VBD	_	_	0	ROOT	_	_
7	that	_	IN	_	_	6	OBJ	_	_
8	Schering-Plough	_	NNP	_	_	9	NAME	_	_
9	Corp.	_	NNP	_	_	13	NMOD	_	_
10	's	_	POS	_	_	9	SUFFIX	_	_
11	expected	_	JJ	_	_	13	NMOD	_	_
12	profit	_	NN	_	_	13	NMOD	_	_
13	rise	_	NN	_	_	32	SBJ	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	about	_	RB	_	_	20	DEP	_	_
16	18	_	CD	_	_	20	DEP	_	_
17	%	_	NN	_	_	20	DEP	_	_
18	to	_	TO	_	_	20	DEP	_	_
19	20	_	CD	_	_	20	DEP	_	_
20	%	_	NN	_	_	14	PMOD	_	_
21	,	_	,	_	_	13	P	_	_
22	and	_	CC	_	_	13	COORD	_	_
23	Bristol-Meyers	_	NNP	_	_	27	NMOD	_	_
24	's	_	POS	_	_	23	SUFFIX	_	_
25	expected	_	JJ	_	_	27	NMOD	_	_
26	profit	_	NN	_	_	27	NMOD	_	_
27	increase	_	NN	_	_	22	CONJ	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	about	_	RB	_	_	31	NMOD	_	_
30	13	_	CD	_	_	29	DEP	_	_
31	%	_	NN	_	_	28	PMOD	_	_
32	are	_	VBP	_	_	7	SUB	_	_
33	largely	_	RB	_	_	34	ADV	_	_
34	because	_	IN	_	_	32	PRD-PRP	_	_
35	``	_	``	_	_	34	P	_	_
36	those	_	DT	_	_	37	NMOD	_	_
37	companies	_	NNS	_	_	38	SBJ	_	_
38	are	_	VBP	_	_	34	SUB	_	_
39	really	_	RB	_	_	38	ADV	_	_
40	managed	_	VBN	_	_	38	VC	_	_
41	well	_	RB	_	_	40	MNR	_	_
42	.	_	.	_	_	6	P	_	_
43	''	_	''	_	_	6	P	_	_

1	ScheringPlough	_	NN	_	_	2	SBJ	_	_
2	earned	_	VBD	_	_	0	ROOT	_	_
3	$	_	$	_	_	2	OBJ	_	_
4	94.4	_	CD	_	_	3	DEP	_	_
5	million	_	CD	_	_	3	DEP	_	_
6	,	_	,	_	_	3	P	_	_
7	or	_	CC	_	_	3	COORD	_	_
8	84	_	CD	_	_	9	NMOD	_	_
9	cents	_	NNS	_	_	7	CONJ	_	_
10	a	_	DT	_	_	11	NMOD	_	_
11	share	_	NN	_	_	9	ADV	_	_
12	,	_	,	_	_	2	P	_	_
13	while	_	IN	_	_	2	ADV	_	_
14	Bristol-Myers	_	NNP	_	_	15	SBJ	_	_
15	earned	_	VBD	_	_	13	SUB	_	_
16	$	_	$	_	_	15	OBJ	_	_
17	232.3	_	CD	_	_	16	DEP	_	_
18	million	_	CD	_	_	16	DEP	_	_
19	,	_	,	_	_	16	P	_	_
20	or	_	CC	_	_	16	COORD	_	_
21	81	_	CD	_	_	22	NMOD	_	_
22	cents	_	NNS	_	_	20	CONJ	_	_
23	a	_	DT	_	_	24	NMOD	_	_
24	share	_	NN	_	_	22	ADV	_	_
25	,	_	,	_	_	15	P	_	_
26	in	_	IN	_	_	15	TMP	_	_
27	the	_	DT	_	_	29	NMOD	_	_
28	like	_	JJ	_	_	29	NMOD	_	_
29	period	_	NN	_	_	26	PMOD	_	_
30	a	_	DT	_	_	31	NMOD	_	_
31	year	_	NN	_	_	32	AMOD	_	_
32	earlier	_	RBR	_	_	29	TMP	_	_
33	.	_	.	_	_	2	P	_	_

1	In	_	IN	_	_	10	LOC	_	_
2	Madison	_	NNP	_	_	1	PMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	N.J.	_	NNP	_	_	2	APPO	_	_
5	,	_	,	_	_	10	P	_	_
6	a	_	DT	_	_	7	NMOD	_	_
7	spokesman	_	NN	_	_	10	SBJ	_	_
8	for	_	IN	_	_	7	NMOD	_	_
9	Schering-Plough	_	NNP	_	_	8	PMOD	_	_
10	said	_	VBD	_	_	0	ROOT	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	company	_	NN	_	_	13	SBJ	_	_
13	has	_	VBZ	_	_	10	OBJ	_	_
14	``	_	``	_	_	16	P	_	_
15	no	_	DT	_	_	16	NMOD	_	_
16	problems	_	NNS	_	_	13	OBJ	_	_
17	''	_	''	_	_	16	P	_	_
18	with	_	IN	_	_	16	NMOD	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	average	_	JJ	_	_	21	NMOD	_	_
21	estimate	_	NN	_	_	18	PMOD	_	_
22	by	_	IN	_	_	21	NMOD	_	_
23	a	_	DT	_	_	24	NMOD	_	_
24	analysts	_	NNS	_	_	22	PMOD	_	_
25	that	_	IN	_	_	21	NMOD	_	_
26	third-quarter	_	JJ	_	_	27	NMOD	_	_
27	earnings	_	NNS	_	_	30	SBJ	_	_
28	per	_	IN	_	_	27	NMOD	_	_
29	share	_	NN	_	_	28	PMOD	_	_
30	rose	_	VBD	_	_	25	SUB	_	_
31	by	_	IN	_	_	30	EXT	_	_
32	about	_	RB	_	_	34	NMOD	_	_
33	19	_	CD	_	_	32	DEP	_	_
34	%	_	NN	_	_	31	PMOD	_	_
35	,	_	,	_	_	30	P	_	_
36	to	_	TO	_	_	30	DIR	_	_
37	$	_	$	_	_	36	PMOD	_	_
38	1	_	CD	_	_	37	NMOD	_	_
39	.	_	.	_	_	10	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	company	_	NN	_	_	3	SBJ	_	_
3	expects	_	VBZ	_	_	25	OBJ	_	_
4	to	_	TO	_	_	3	OPRD	_	_
5	achieve	_	VB	_	_	4	IM	_	_
6	the	_	DT	_	_	9	NMOD	_	_
7	20	_	CD	_	_	8	AMOD	_	_
8	%	_	NN	_	_	9	NMOD	_	_
9	increase	_	NN	_	_	5	OBJ	_	_
10	in	_	IN	_	_	9	LOC	_	_
11	full-year	_	JJ	_	_	12	NMOD	_	_
12	earnings	_	NNS	_	_	10	PMOD	_	_
13	per	_	IN	_	_	9	NMOD	_	_
14	share	_	NN	_	_	13	PMOD	_	_
15	,	_	,	_	_	5	P	_	_
16	as	_	IN	_	_	5	ADV	_	_
17	it	_	PRP	_	_	18	SBJ	_	_
18	projected	_	VBD	_	_	16	SUB	_	_
19	in	_	IN	_	_	18	ADV	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	spring	_	NN	_	_	19	PMOD	_	_
22	,	_	,	_	_	25	P	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	spokesman	_	NN	_	_	25	SBJ	_	_
25	said	_	VBD	_	_	0	ROOT	_	_
26	.	_	.	_	_	25	P	_	_

1	Meanwhile	_	RB	_	_	4	TMP	_	_
2	,	_	,	_	_	4	P	_	_
3	analysts	_	NNS	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	Pfizer	_	NNP	_	_	8	NMOD	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	recent	_	JJ	_	_	8	NMOD	_	_
8	string	_	NN	_	_	13	SBJ	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	lackluster	_	JJ	_	_	12	NMOD	_	_
11	quarterly	_	JJ	_	_	12	NMOD	_	_
12	performances	_	NNS	_	_	9	PMOD	_	_
13	continued	_	VBD	_	_	4	OBJ	_	_
14	,	_	,	_	_	13	P	_	_
15	as	_	IN	_	_	13	ADV	_	_
16	earnings	_	NNS	_	_	20	SBJ	_	_
17	in	_	IN	_	_	16	TMP	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	quarter	_	NN	_	_	17	PMOD	_	_
20	were	_	VBD	_	_	15	SUB	_	_
21	expected	_	VBN	_	_	20	VC	_	_
22	to	_	TO	_	_	21	OPRD	_	_
23	decline	_	VB	_	_	22	IM	_	_
24	by	_	IN	_	_	23	EXT	_	_
25	about	_	RB	_	_	27	NMOD	_	_
26	5	_	CD	_	_	25	DEP	_	_
27	%	_	NN	_	_	24	PMOD	_	_
28	.	_	.	_	_	4	P	_	_

1	Sales	_	NNP	_	_	20	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	Pfizer	_	NNP	_	_	6	NMOD	_	_
4	's	_	POS	_	_	3	SUFFIX	_	_
5	important	_	JJ	_	_	6	NMOD	_	_
6	drugs	_	NNS	_	_	2	PMOD	_	_
7	,	_	,	_	_	6	P	_	_
8	Feldene	_	NNP	_	_	6	APPO	_	_
9	for	_	IN	_	_	8	NMOD	_	_
10	treating	_	VBG	_	_	9	PMOD	_	_
11	arthritis	_	NN	_	_	10	OBJ	_	_
12	,	_	,	_	_	8	P	_	_
13	and	_	CC	_	_	8	COORD	_	_
14	Procardia	_	NNP	_	_	13	CONJ	_	_
15	,	_	,	_	_	14	P	_	_
16	a	_	DT	_	_	18	NMOD	_	_
17	heart	_	NN	_	_	18	NMOD	_	_
18	medicine	_	NN	_	_	14	APPO	_	_
19	,	_	,	_	_	14	P	_	_
20	have	_	VBP	_	_	0	ROOT	_	_
21	shrunk	_	VBN	_	_	20	VC	_	_
22	because	_	RB	_	_	23	DEP	_	_
23	of	_	IN	_	_	21	PRP	_	_
24	increased	_	JJ	_	_	25	NMOD	_	_
25	competition	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	20	P	_	_

1	``	_	``	_	_	17	P	_	_
2	The	_	DT	_	_	6	NMOD	_	_
3	(	_	(	_	_	4	P	_	_
4	strong	_	JJ	_	_	6	PRN	_	_
5	)	_	)	_	_	4	P	_	_
6	dollar	_	NN	_	_	7	SBJ	_	_
7	hurt	_	VBD	_	_	17	OBJ	_	_
8	Pfizer	_	NNP	_	_	7	OBJ	_	_
9	a	_	DT	_	_	10	NMOD	_	_
10	lot	_	NN	_	_	7	ADV	_	_
11	,	_	,	_	_	7	P	_	_
12	too	_	RB	_	_	7	ADV	_	_
13	,	_	,	_	_	17	P	_	_
14	''	_	''	_	_	17	P	_	_
15	Mr.	_	NNP	_	_	16	TITLE	_	_
16	Sweig	_	NNP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

1	In	_	IN	_	_	9	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	third	_	JJ	_	_	4	NMOD	_	_
4	quarter	_	NN	_	_	1	PMOD	_	_
5	last	_	JJ	_	_	6	NMOD	_	_
6	year	_	NN	_	_	9	TMP	_	_
7	,	_	,	_	_	9	P	_	_
8	Pfizer	_	NNP	_	_	9	SBJ	_	_
9	earned	_	VBD	_	_	0	ROOT	_	_
10	$	_	$	_	_	9	OBJ	_	_
11	216.8	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	,	_	,	_	_	10	P	_	_
14	or	_	CC	_	_	10	COORD	_	_
15	$	_	$	_	_	14	CONJ	_	_
16	1.29	_	CD	_	_	15	NMOD	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	15	ADV	_	_
19	.	_	.	_	_	9	P	_	_

1	In	_	IN	_	_	7	LOC	_	_
2	New	_	NNP	_	_	3	NAME	_	_
3	York	_	NNP	_	_	1	PMOD	_	_
4	,	_	,	_	_	7	P	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	company	_	NN	_	_	7	SBJ	_	_
7	declined	_	VBD	_	_	0	ROOT	_	_
8	comment	_	NN	_	_	7	OBJ	_	_
9	.	_	.	_	_	7	P	_	_

1	Analysts	_	NNS	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	they	_	PRP	_	_	4	SBJ	_	_
4	expected	_	VBD	_	_	2	OBJ	_	_
5	Upjohn	_	NNP	_	_	7	NMOD	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	profit	_	NN	_	_	4	OBJ	_	_
8	to	_	TO	_	_	4	OPRD	_	_
9	be	_	VB	_	_	8	IM	_	_
10	flat	_	JJ	_	_	9	PRD	_	_
11	or	_	CC	_	_	9	COORD	_	_
12	rise	_	VB	_	_	11	CONJ	_	_
13	by	_	IN	_	_	12	EXT	_	_
14	only	_	RB	_	_	20	DEP	_	_
15	about	_	RB	_	_	20	DEP	_	_
16	2	_	CD	_	_	20	DEP	_	_
17	%	_	NN	_	_	20	DEP	_	_
18	to	_	TO	_	_	20	DEP	_	_
19	4	_	CD	_	_	20	DEP	_	_
20	%	_	NN	_	_	13	PMOD	_	_
21	as	_	IN	_	_	20	NMOD	_	_
22	compared	_	VBN	_	_	21	SUB	_	_
23	with	_	IN	_	_	22	ADV	_	_
24	$	_	$	_	_	23	PMOD	_	_
25	89.6	_	CD	_	_	24	DEP	_	_
26	million	_	CD	_	_	24	DEP	_	_
27	,	_	,	_	_	24	P	_	_
28	or	_	CC	_	_	24	COORD	_	_
29	49	_	CD	_	_	30	NMOD	_	_
30	cents	_	NNS	_	_	28	CONJ	_	_
31	a	_	DT	_	_	32	NMOD	_	_
32	share	_	NN	_	_	30	ADV	_	_
33	,	_	,	_	_	24	P	_	_
34	it	_	PRP	_	_	35	SBJ	_	_
35	earned	_	VBD	_	_	24	NMOD	_	_
36	a	_	DT	_	_	37	NMOD	_	_
37	year	_	NN	_	_	38	AMOD	_	_
38	ago	_	RB	_	_	35	TMP	_	_
39	.	_	.	_	_	2	P	_	_

1	Upjohn	_	NNP	_	_	4	NMOD	_	_
2	's	_	POS	_	_	1	SUFFIX	_	_
3	biggest-selling	_	JJ	_	_	4	NMOD	_	_
4	drugs	_	NNS	_	_	5	SBJ	_	_
5	are	_	VBP	_	_	0	ROOT	_	_
6	Xanax	_	NNP	_	_	5	PRD	_	_
7	,	_	,	_	_	6	P	_	_
8	a	_	DT	_	_	9	NMOD	_	_
9	tranquilizer	_	NN	_	_	6	APPO	_	_
10	,	_	,	_	_	6	P	_	_
11	and	_	CC	_	_	6	COORD	_	_
12	Halcion	_	NNP	_	_	11	CONJ	_	_
13	,	_	,	_	_	12	P	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	sedative	_	NN	_	_	12	APPO	_	_
16	.	_	.	_	_	5	P	_	_

1	Sales	_	NNS	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	both	_	DT	_	_	4	NMOD	_	_
4	drugs	_	NNS	_	_	2	PMOD	_	_
5	have	_	VBP	_	_	0	ROOT	_	_
6	been	_	VBN	_	_	5	VC	_	_
7	hurt	_	VBN	_	_	6	VC	_	_
8	by	_	IN	_	_	7	LGS	_	_
9	new	_	JJ	_	_	11	NMOD	_	_
10	state	_	NN	_	_	11	NMOD	_	_
11	laws	_	NNS	_	_	8	PMOD	_	_
12	restricting	_	VBG	_	_	11	APPO	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	prescriptions	_	NNS	_	_	12	OBJ	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	certain	_	JJ	_	_	18	NMOD	_	_
17	tranquilizing	_	JJ	_	_	18	NMOD	_	_
18	medicines	_	NNS	_	_	15	PMOD	_	_
19	and	_	CC	_	_	11	COORD	_	_
20	adverse	_	JJ	_	_	21	NMOD	_	_
21	publicity	_	NN	_	_	19	CONJ	_	_
22	about	_	IN	_	_	21	NMOD	_	_
23	the	_	DT	_	_	25	NMOD	_	_
24	excessive	_	JJ	_	_	25	NMOD	_	_
25	use	_	NN	_	_	22	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	drugs	_	NNS	_	_	26	PMOD	_	_
29	.	_	.	_	_	5	P	_	_

1	Also	_	RB	_	_	47	OBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	company	_	NN	_	_	7	NMOD	_	_
5	's	_	POS	_	_	4	SUFFIX	_	_
6	hair-growing	_	JJ	_	_	7	NMOD	_	_
7	drug	_	NN	_	_	11	SBJ	_	_
8	,	_	,	_	_	7	P	_	_
9	Rogaine	_	NNP	_	_	7	APPO	_	_
10	,	_	,	_	_	7	P	_	_
11	is	_	VBZ	_	_	1	COORD	_	_
12	selling	_	VBG	_	_	11	VC	_	_
13	well	_	RB	_	_	12	MNR	_	_
14	--	_	:	_	_	12	P	_	_
15	at	_	IN	_	_	12	ADV	_	_
16	about	_	RB	_	_	17	DEP	_	_
17	$	_	$	_	_	15	PMOD	_	_
18	125	_	CD	_	_	17	DEP	_	_
19	million	_	CD	_	_	17	DEP	_	_
20	for	_	IN	_	_	17	NMOD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	year	_	NN	_	_	20	PMOD	_	_
23	,	_	,	_	_	11	P	_	_
24	but	_	CC	_	_	11	COORD	_	_
25	the	_	DT	_	_	26	NMOD	_	_
26	company	_	NN	_	_	28	NMOD	_	_
27	's	_	POS	_	_	26	SUFFIX	_	_
28	profit	_	NN	_	_	32	SBJ	_	_
29	from	_	IN	_	_	28	NMOD	_	_
30	the	_	DT	_	_	31	NMOD	_	_
31	drug	_	NN	_	_	29	PMOD	_	_
32	has	_	VBZ	_	_	24	CONJ	_	_
33	been	_	VBN	_	_	32	VC	_	_
34	reduced	_	VBN	_	_	33	VC	_	_
35	by	_	IN	_	_	34	LGS	_	_
36	Upjohn	_	NNP	_	_	39	NMOD	_	_
37	's	_	POS	_	_	36	SUFFIX	_	_
38	expensive	_	JJ	_	_	39	NMOD	_	_
39	print	_	NN	_	_	35	PMOD	_	_
40	and	_	CC	_	_	39	COORD	_	_
41	television	_	NN	_	_	42	NMOD	_	_
42	campaigns	_	NNS	_	_	40	CONJ	_	_
43	for	_	IN	_	_	39	NMOD	_	_
44	advertising	_	VBG	_	_	43	PMOD	_	_
45	,	_	,	_	_	47	P	_	_
46	analysts	_	NNS	_	_	47	SBJ	_	_
47	said	_	VBD	_	_	0	ROOT	_	_
48	.	_	.	_	_	47	P	_	_

1	In	_	IN	_	_	7	LOC	_	_
2	Kalamazoo	_	NNP	_	_	1	PMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	Mich.	_	NNP	_	_	2	APPO	_	_
5	,	_	,	_	_	2	P	_	_
6	Upjohn	_	NNP	_	_	7	SBJ	_	_
7	declined	_	VBD	_	_	0	ROOT	_	_
8	comment	_	NN	_	_	7	OBJ	_	_
9	.	_	.	_	_	7	P	_	_

